SCHEMBL1122006

SCHEMBL1122006

O=CCc1ccc(F)cc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.48
AGXT P21549 2/20 0.48
KDM4E B2RXH2 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
DAO P14920 1/20 0.41
HTR2A P28223 3/20 0.39
HTR2C P28335 3/20 0.39
MAOB P27338 1/20 0.39
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
GSK3B P49841 1/20 0.39
BACE1 P56817 1/20 0.39
RIPK1 Q13546 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KCNH2 Q12809 1/20 0.37
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29953348 1.00 IDO1 (0.48) IDO1AGXTKDM4ESMN1; SMN2DAO
SCHEMBL3121227 0.83 PSEN1 (0.43) IDO1AGXTCES2CES1RIPK1
SCHEMBL29954553 0.83 PSEN1 (0.43) IDO1AGXTCES2CES1RIPK1
SCHEMBL1569775 0.81 CA3 (0.46) IDO1AGXTKDM4EDAOMAOB
SCHEMBL9027842 0.81 ALDH1A1 (0.41) IDO1AGXTALDH1A1MEN1KMT2A
SCHEMBL1554674 0.79 CHRNA7 (0.46) ALDH1A1
SCHEMBL14095120 0.79 TRPV4 (0.38)
SCHEMBL895534 0.79 IDO1 (0.50) IDO1AGXTKDM4ESMN1; SMN2DAO
SCHEMBL8205 0.79 PDPK1 (0.43)
SCHEMBL13985969 0.79 ERN1 (0.34) IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188110-A1 SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) 2025-06-12 US disclosed
EP-4384519-A1 SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION Albert-Ludwigs-Universität Freiburg (DE) 2024-06-19 EP disclosed
WO-2023210623-A1 HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME 株式会社エス・ディー・エス バイオテック 2023-11-02 WO disclosed
WO-2023017152-A1 SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) 2023-02-16 WO disclosed
US-11319300-B2 Polyfluoro-substituted aromatic heterocyclic derivative, pharmaceutical composition containing same, and applications thereof GUANGZHOU LIXIN PHARMACEUTICAL CO., LTD. (CN) 2022-05-03 US disclosed
CN-108341801-B Polyfluoro-substituted aromatic heterocycle derivatives, pharmaceutical composition containing polyfluoro-substituted aromatic heterocycle derivatives and application of polyfluoro-substituted aromatic heterocycle derivatives 浙江大学 2020-05-12 CN disclosed
EP-3414251-A1 THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS Forma Therapeutics, Inc. (US) 2018-12-19 EP disclosed
EP-3414252-A1 THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS Forma Therapeutics, Inc. (US) 2018-12-19 EP disclosed
WO-2018137555-A1 POLYFLUORO-SUBSTITUTED AROMATIC HETEROCYCLIC COMPOUND DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND APPLICATIONS THEREOF 浙江大学 2018-08-02 WO disclosed
CN-108341801-A Polyfluoro substitution virtue connection heterocyclic derivative, the pharmaceutical composition containing it and its application 浙江大学 2018-07-31 CN disclosed
WO-2003076405-A1 MONOCYCLIC AROYLPYRIDINONES AS ANTIINFLAMMATORY AGENTS BAYER HEALTHCARE AG (DE) 2003-09-18 WO disclosed
WO-2003053967-A1 AROYL PYRIDINONES BAYER HEALTHCARE AG (DE) 2003-07-03 WO disclosed
US-20020103400-A1 Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same CENTRAL GLASS COMPANY, LIMITED (JP) 2002-08-01 US disclosed
EP-1068200-A1 2,4,4-TRISUBSTITUTED-1,3-DIOXOLANE ANTIFUNGALS JANSSEN PHARMACEUTICA N.V. (BE) 2001-01-17 EP disclosed
CN-1272111-A Tricyclic vasopressin agonists AMERICAN HOME PROD (US) 2000-11-01 CN disclosed
EP-1000062-A1 TRICYCLIC VASOPRESSIN AGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-05-17 EP disclosed
WO-1999006409-A1 TRICYCLIC VASOPRESSIN AGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 1999-02-11 WO disclosed
WO-1999002523-A1 2,4,4-TRISUBSTITUTED-1,3-DIOXOLANE ANTIFUNGALS JANSSEN PHARMACEUTICA N.V. (BE) 1999-01-21 WO disclosed
US-4267359-A Novel carboxylic acid esters ZOECON CORPORATION (US) 1981-05-12 US disclosed
US-4204071-A 4-Aryl-3-butenoic acids and lower alkyl esters ZOECON CORPORATION (US) 1980-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188110-A1 SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION KMT5A, KMT5B, KMT5C IDO1 2116/4885AGXT 608/4885KDM4E 8/4885
US-11319300-B2 Polyfluoro-substituted aromatic heterocyclic derivative, pharmaceutical composition containing same, and applications thereof AKT1, AKT2, AKT3 IDO1 2400/4885AGXT 2005/4885KDM4E 2725/4885
US-20020103400-A1 Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same MAP2K5, MAP2K4, MAP2K1 IDO1 520/4885AGXT 1110/4885KDM4E 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.